An international CRO with a multi-country operational platformThe target company is an independent player recognized for the quality and scope of its clinical operations. With an operational presence in several countries, the target company manages multicenter projects within diverse regulatory frameworks. A structured transactional framework that conforms to the Oxurion model• Oxurion plans to acquire 75% of the target company's share capital. ?the target company at €3,712,500 on a 100% basis. During this period, the target company and its sellers agree not to initiate or maintain discussions with third parties regarding any competing transaction.

Source: The North Africa Journal March 20, 2026 08:00 UTC